Semimechanistic Pharmacokinetic-Pharmacodynamic Model with Adaptation Development for Time-Kill Experiments of Ciprofloxacin against Pseudomonasaeruginosa

ABSTRACT The objective of this study was to implement a semimechanistic pharmacokinetic-pharmacodynamic (PK-PD) model to describe the effects of ciprofloxacin against Pseudomonasaeruginosa in vitro. Time-kill curves were generated with an initial inoculum close to 5 × 106CFU/ml of P. aeruginosa PAO1 and constant ciprofloxacin concentrations between 0.12 and 4.0 μg/ml (corresponding to 0.5× and 16× MIC). To support the model, phenotypic experiments were conducted with the PAO7H mutant strain, which overexpresses the MexEF OprN efflux pump and phenyl arginine β-naphthylamide (PAβN), a known efflux inhibitor of main Mex multidrug efflux systems. A population approach was used for parameter estimation. At subinhibitory ciprofloxacin concentrations (0.12 and 0.25 μg/ml), an initial CFU decay followed by regrowth was observed, attesting to rapid emergence of bacteria with increased but moderate resistance (8-fold increase of MIC). This phenomenon was mainly due to an overexpression of the Mex protein efflux pumps, as shown by a 16-fold diminution of the MIC in the presence of PAβN in these strains with low-level resistance. A PK-PD model with adaptation development was successfully used to describe these data. However, additional experiments are required to validate the robustness of this model after longer exposure periods and multiple dosing regimens, as well as in vivo.

[1]  W. Couet,et al.  Mechanism-Based Pharmacokinetic-Pharmacodynamic Models of In Vitro Fungistatic and Fungicidal Effects against Candida albicans , 2008, Antimicrobial Agents and Chemotherapy.

[2]  P. McNamara,et al.  Mechanism-Based Pharmacodynamic Models of Fluoroquinolone Resistance in Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.

[3]  K. Drlica,et al.  DNA gyrase, topoisomerase IV, and the 4-quinolones , 1997, Microbiology and molecular biology reviews : MMBR.

[4]  A. Vinks,et al.  Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion , 1997, Antimicrobial agents and chemotherapy.

[5]  I. Gould,et al.  Ionic binding, adaptive resistance and post-antibiotic effect of netilmicin and ciprofloxacin. , 1991, The Journal of antimicrobial chemotherapy.

[6]  Mats O. Karlsson,et al.  Semimechanistic Pharmacokinetic/Pharmacodynamic Model for Assessment of Activity of Antibacterial Agents from Time-Kill Curve Experiments , 2006, Antimicrobial Agents and Chemotherapy.

[7]  M. Maciá,et al.  Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.

[8]  Michael Nikolaou,et al.  Modelling time-kill studies to discern the pharmacodynamics of meropenem. , 2005, The Journal of antimicrobial chemotherapy.

[9]  Neang S. Ly,et al.  Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.

[10]  E. Bingen,et al.  Pseudomonas aeruginosa May Accumulate Drug Resistance Mechanisms without Losing Its Ability To Cause Bloodstream Infections , 2007, Antimicrobial Agents and Chemotherapy.

[11]  R. MacLaren,et al.  Nosocomial Infections Due to Multidrug‐Resistant Pseudomonas aeruginosa: Epidemiology and Treatment Options , 2005, Pharmacotherapy.

[12]  B. Marquez Bacterial efflux systems and efflux pumps inhibitors. , 2005, Biochimie.

[13]  D. Hooper Mechanisms of fluoroquinolone resistance. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[14]  P. Tulkens,et al.  A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. , 2007, The Journal of antimicrobial chemotherapy.

[15]  E. Schuck,et al.  Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Once-Daily Treatment Using Ciprofloxacin in an Extended-Release Dosage Form* , 2005, Infection.

[16]  H. Nikaido,et al.  Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa , 1995, Antimicrobial agents and chemotherapy.

[17]  Robert Leary,et al.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. , 2003, The Journal of clinical investigation.

[18]  H. Derendorf,et al.  Pharmacokinetic-Pharmacodynamic Modeling of the In Vitro Activities of Oxazolidinone Antimicrobial Agents against Methicillin-Resistant Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.

[19]  J. Ruiz Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. , 2003, The Journal of antimicrobial chemotherapy.

[20]  J. Karlowsky,et al.  Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa. , 2004, International journal of antimicrobial agents.

[21]  M. Maciá,et al.  Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents , 2007, Antimicrobial Agents and Chemotherapy.

[22]  H. Schweizer Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. , 2003, Genetics and molecular research : GMR.

[23]  G. Jacoby Mechanisms of resistance to quinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  A. Wong-Beringer,et al.  Use of an Efflux Pump Inhibitor To Determine the Prevalence of Efflux Pump-Mediated Fluoroquinolone Resistance and Multidrug Resistance in Pseudomonas aeruginosa , 2005, Antimicrobial Agents and Chemotherapy.

[25]  William J Jusko,et al.  Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[26]  Angela Lee,et al.  MexXY-OprM Efflux Pump Is Necessary for Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides , 2003, Antimicrobial Agents and Chemotherapy.

[27]  G. Manfreda,et al.  Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa. , 2007, Veterinary microbiology.

[28]  K. Rand,et al.  Determination of free extracellular concentrations of piperacillin by microdialysis. , 1996, Journal of pharmaceutical sciences.

[29]  H. Nikaido,et al.  Involvement of an Active Efflux System in the Natural Resistance of Pseudomonas aeruginosa to Aminoglycosides , 1999, Antimicrobial Agents and Chemotherapy.

[30]  P. Tulkens,et al.  Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. , 2003, The Journal of antimicrobial chemotherapy.

[31]  K. Rodvold,et al.  Pharmacokinetics and Pharmacodynamics of Fluoroquinolones , 2001, Pharmacotherapy.

[32]  O. Cars,et al.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. , 2005, The Journal of antimicrobial chemotherapy.

[33]  S. Leibler,et al.  Bacterial Persistence as a Phenotypic Switch , 2004, Science.

[34]  L. Rubin,et al.  Stability of Antibiotics Used for Antibiotic-Lock Treatment of Infections of Implantable Venous Devices (Ports) , 1999, Antimicrobial Agents and Chemotherapy.

[35]  J. Blaser,et al.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance , 1987, Antimicrobial Agents and Chemotherapy.

[36]  A. Yamaguchi,et al.  Type II Topoisomerase Mutations in Fluoroquinolone-Resistant Clinical Strains of Pseudomonas aeruginosa Isolated in 1998 and 1999: Role of Target Enzyme in Mechanism of Fluoroquinolone Resistance , 2001, Antimicrobial Agents and Chemotherapy.

[37]  Y. Yamano,et al.  Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model. , 2008, Journal of pharmaceutical sciences.